Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
By John Harbison|2017-02-20T06:55:48-08:00September 29, 2016|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
